share_log

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

Benzinga ·  Nov 12 05:50  · Ratings

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment